Cogent Biosciences Q1 EPS $(0.62) Misses $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences reported a Q1 EPS loss of $(0.62), missing the consensus estimate of $(0.51) by 21.57%. This represents a 14.81% increase in losses compared to the same period last year.
May 07, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cogent Biosciences reported a larger than expected Q1 loss of $(0.62) per share, missing the $(0.51) estimate and showing a 14.81% increase in losses from the previous year.
Missing the earnings estimate by 21.57% and reporting a year-over-year increase in losses by 14.81% is likely to negatively impact investor sentiment and could lead to a short-term decrease in COGT's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100